Dr Arun Swaminathan – Improving the Diagnosis and Treatment of Neurological Diseases
Medical conditions that affect the brain can have severe impacts on people’s lives. Many of these conditions can be difficult to treat, including epilepsy which affects the brain to cause seizures and the common form of dementia known as Alzheimer’s disease. Dr Arun Swaminathan at the University of Nebraska Medical Center specialises in the treatment of epilepsy. He also collaborates with fellow researchers to explore treatment options for Alzheimer’s disease.
Finding the Best Treatments for Epilepsy
Across the globe, approximately 50 million people suffer from epilepsy. The majority of people who are diagnosed are prescribed anti-seizure medication to prevent seizures from occurring. However, a large number (about 25–30% of patients) are unresponsive to the treatment and require surgery. The surgery involves removing small parts of the brain that are thought to influence the seizures. Surgery has variable outcomes and success is dependent on many factors. These include the affected area of the brain and its baseline function as well as the surgical technique used.
Dr Arun Swaminathan at the University of Nebraska Medical Center and his colleagues sought to evaluate the treatment outcomes of epilepsy patients up to 20 years post-surgery. The researchers used past patient data to compare patients who had received a scalp electroencephalogram (EEG) or intracranial EEG. An EEG is a test that records the electrical wave patterns of the brain and can indicate if the brain activity is abnormal. This can be performed by either placing metal disks on the scalp, known as scalp EEG, or by placing electrodes into the brain (intracranial). Once this has taken place, surgery is performed and the outcome can be assessed using the Engel Epilepsy Surgery Outcome Scale. This ranges from the classification of an individual as being free of disabling features, to having rare seizures, demonstrating some improvement or finally, no worthwhile improvement or worsening.
Dr Swaminathan and his team observed that epilepsy surgery has good long-term outcomes in most patients. Those who had a temporal region of the brain removed, which is involved in hearing and speech, had the best outcome with scalp EEG alone, provided they had concomitant testing supporting pure temporal epilepsy only. Additionally, they found that some patients could suffer from cognitive problems such as memory loss, as well as depression or psychosis if they had surgery on the frontal region of the brain that is involved with cognitive skills, albeit these were mild in most patients that had them. The researchers also observed that using intracranial EEG had similar efficacy in finding the seizure onset zones as taking scans or images of the brain prior to the surgery in many patients.
Importantly, epileptic episodes do not always present as convulsive seizures. Some seizures can go unnoticed without any obvious clinical signs. This is dangerous as it can lead to delayed treatment response and result in the death of a patient. Dr Swaminathan and his team evaluated the use of EEG to detect nonconvulsive seizures using past patient data to see if experts could diagnose patients correctly given their EEG results. They also evaluated the best way to arrange the electrodes or metal plates onto the head for accurate diagnosis, otherwise referred to as a montage. They showed that the EEG could differentiate between normal and seizure-like wave patterns effectively and that a limited montage could provide sufficient efficacy in certain situations, especially if there were time constraints.
Learning from Experience to Improve Patient Care
Most medical conditions can be diagnosed using standard testing and tell-tale symptoms. Yet not every individual will present the usual symptoms that are associated with signs of a disease. Clinicians can take note of this and publish case reports to spread awareness of uncommon symptoms of a disease that have been observed in individual patients.
Dr Swaminathan observed that a patient with a genetic condition known as spinocerebellar ataxia type 8 was having seizures. This inherited condition leads to problems with movement, balance and coordination. Dr Swaminathan’s patient was also suffering from weakness over one side of the body and brain malfunction. Although seizures are rare for somebody suffering from this condition, Dr Swaminathan concluded that it was causing nonconvulsive seizures which could be treated using anti-epileptic therapy. This treatment resulted in an improvement for the patient. Dr Swaminathan thus suggests that even if seizures are a rare occurrence in somebody with a condition that affects the brain, patients should still see an epilepsy expert to speed up diagnosis and treatment for seizures.
Dr Swaminathan has also drawn from his experience observing patients to propose a novel way to diagnose cancer of the larynx or ‘voice box’. He identified that a 59-year-old patient was suffering from autoimmune encephalitis. This condition occurs when the body’s immune system, responsible for fighting infections and unhealthy cells, attacks healthy brain cells instead.
The patient was treated with anti-epileptic drugs and steroids to prevent seizures and reduce the activity of the immune system. Although the patient recovered, they returned to hospital a year later and was found to have a cancerous tumour on the larynx. The only indicator of this was high levels of striational antibodies which attack the proteins that make up muscle. Dr Swaminathan suggested that the cancer had caused the autoimmune condition and that although rare, the presence of striational antibodies could be used to diagnose this condition in other patients with similar presentations as well.
A Novel Treatment for Epilepsy?
In many countries, cannabis is an illegal drug. However, in recent years it has been legalised to treat medical conditions including refractory epilepsy. Refractory epilepsy is a severe form of epilepsy that does not respond to recommended treatments. Cannabidiol (or CBD oil) is a chemical that is extracted from the cannabis plant and has been approved by the US Food and Drug Administration to treat epilepsy and prevent seizures in patients with refractory epilepsy syndromes like Lennox Gastaut Syndrome or Dravet’s Syndrome.
Dr Swaminathan and his colleagues used EEG and graphs to measure changes in brain network dynamics when patients with previously untreatable epilepsy are administered CBD. Brain network dynamics describe how parts of the brain connect and interact with one another and how this leads to changes in brain activity. Dr Swaminathan and his fellow researchers showed that treatment with CBD led to changes in brain network dynamics that could reduce seizures and that some of these brain network signals could predict which patients would be more likely to respond to CBD treatment. This opens up a new avenue to promote exploration of CBD as a treatment option for epilepsy in patients who have been previously difficult to treat.
Food for Thought
Further surprising treatment options have been proposed to treat epilepsy. Since the 1930s, it has been suggested that a ketogenic diet can prevent seizures in children and teenagers who suffer from refractory epilepsy. A ketogenic diet is a low carbohydrate, high fat diet which has become a trendy way to lose weight, but the exact mechanism of how this may prevent seizures is unknown.
Dr Swaminathan and his fellow researchers reviewed four different diet therapies and their effects on young patients from previous research. They concluded that there is no superior ketogenic diet that can be used to treat seizures in young patients but that some patients do respond better than others. They also pointed to the importance of maintaining a balanced diet for long-term health.
Other conditions that affect the brain may also be treated using a nutritional approach. Alzheimer’s disease is a form of dementia leading to irreversible memory loss and impairments to cognition that eventually reduce the patient’s quality of life and ability to self-care. Although it affects a large number of individuals, there is no known cure.
Nutritional approaches to slow, prevent or stop the progression of Alzheimer’s disease have been investigated. Dr Swaminathan and colleagues reviewed several of these approaches including the use of vitamins, antioxidants, plant flavonoids and omega-3 fatty acids. Despite being a safe treatment option, unfortunately, there is no overwhelming evidence that any of these approaches can reverse the effects of the disease. More optimistically, Dr Swaminathan suggests that nutritional interventions may still be able to supplement other approaches and improve treatment outcome along with improving the probability of preventing such diseases.
Using Artificial Intelligence for Diagnostics
Not only is Alzheimer’s disease difficult to treat, but it is also hard to diagnose. Numerous methods have been proposed as potential diagnostic tests, including scanning the brain and assessing performance on psychological measures. Unfortunately, these methods can be imprecise or limited, prompting Dr Swaminathan and colleagues to seek out the use of novel technology to improve diagnostic approaches.
Artificial intelligence (AI) involves teaching computers to think and work like humans and comes with numerous applications. Dr Swaminathan and his collaborators used a branch of AI known as ‘deep learning’ to train a computer model to be able to classify whether a patient has Alzheimer’s using brain images taken by an MRI scan. They then tested the computer model with patient data and found that the model could accurately diagnose Alzheimer’s disease. Critically, further investigation could lead to this being used within clinical settings and to study other kinds of dementia and neurodegenerative disease as well.
As we can see, Dr Swaminathan’s clinical and research work extends beyond the field of epilepsy to improve the diagnosis, treatment, and ultimately, quality of life for patients with a broad range of neurological diseases.
Meet the researcher
Dr Arun Swaminathan
University of Nebraska Medical Center
Dr Arun Swaminathan is an Assistant Professor at the University of Nebraska Medical Center. He gained his medical degree from Lokmanya Tilak Medical College in Mumbai in 2004. He then moved to the USA to undertake a residency in neurology. Before commencing his current role, Dr Swaminathan undertook a clinical neurophysiology and epilepsy fellowship at the University of Pennsylvania. He now specialises in the treatment of epilepsy and works at a level 4 centre, which offers the highest level of epilepsy care for all patients. Dr Swaminathan is involved in aspects of epilepsy care, including diagnostics, treatment and epilepsy surgery. He is also involved in the field of research and has collaborated extensively with fellow researchers to explore treatment and diagnosis of epilepsy and Alzheimer’s disease. He hopes that his research can be implemented to improve the lives of patients with these diseases.
David Anderson PhD, University of Nebraska Medical Center
Vijaya Kolachalama PhD, Boston University
Olha Taraschenko MD PhD, University of Nebraska Medical Center
Deepak Madhavan MD MBA, Boys Town Hospital
S Qiu, PS Joshi, MI Miller, et al., Development and validation of an interpretable deep learning framework for Alzheimer’s disease classification, Brain, 2020, 143, 1920–1933.
A Swaminathan, Striational Muscle Antibody Positivity Heralding a Diagnosis of Autoimmune Encephalitis associated with Epiglottic Squamous Cell Carcinoma: A Case Report, Global Journal of Medical Research, 2020, 20, 8-F.
J Wells, A Swaminathan, J Paseka, C Hanson, Efficacy and Safety of a Ketogenic Diet in Children and Adolescents with Refractory Epilepsy-A Review, Nutrients, 2020, 12(6), 1809.
N Swingle, A Vuppala, P Datta et al., Olga Limited-Montage EEG as a Tool for the Detection of Nonconvulsive Seizures, Journal of Clinical Neurophysiology, 2020, doi:10.1097/WNP.0000000000000742.
DE Anderson, D Madhavan, A Swaminathan, Global brain network dynamics predict therapeutic responsiveness to cannabidiol treatment for refractory epilepsy, Brain Communications, 2020, fcaa140.
A Swaminathan, Epilepsy in spinocerebellar ataxia type 8: a case report, Journal of Medical Case Reports, 2019, 13, 333.
A Swaminathan, GA Jicha, Nutrition and prevention of Alzheimer’s dementia, Frontiers in Aging Neuroscience, 2014, 6, 282.
Want to republish our articles?
We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more
Creative Commons Licence
(CC BY 4.0)
This work is licensed under a Creative Commons Attribution 4.0 International License.
What does this mean?
Share: You can copy and redistribute the material in any medium or format
Adapt: You can change, and build upon the material for any purpose, even commercially.
Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
More articles you may like
Professor Michael Ryan | What the Ugandan Response to HIV/AIDS Can Teach Us About Collaborative Governance
Persistent problems such as poverty, disease and hunger are of critical interest to organisation and management scholars. Developing countries often struggle with intractable social issues, including susceptibility to epidemics. The complexity of these challenges means it can be difficult for leaders to organise governance and ensure that resources and capabilities are effectively coordinated. Professor Michael Ryan looks at the case study of the HIV/AIDS response in Uganda, and asks how this can contribute to our understanding of public organisation and state capacity. In particular, he explores how Uganda was successful in using collaborative governance to manage the HIV/AIDS crisis.
Adipose tissue is more commonly known as body fat. Unlike white adipose tissue, which is linked to negative cardiovascular outcomes such as metabolic syndrome, brown adipose tissue is positively related to health and may reduce the risk of cardiometabolic diseases. Professor Aaron Brown and his team at the MaineHealth Institute for Research are working to understand brown adipose tissue regulation and explore its therapeutic potential. They have already made significant advancements through the application of optogenetics, a cutting-edge technique that harnesses the power of light to precisely manipulate specific cellular processes.
Who gets to be a theorist? What kinds of theoretical work get marginalised in academic research? And how does this oppression play out in the peer-review process? Dr Kimberly Kay Hoang is a Professor of Sociology at the University of Chicago. She has explored how difficult it is to get your sociology research published if you are not using research deemed to be legitimate by reviewers. She brings awareness to these issues and argues for change amongst scholars so that new forms of knowledge are not missed, especially regarding feminist, minority and racial theories.
The anonymous leak of the Panama Papers in 2016 revealed how the exceptionally wealthy (such as politicians, celebrities and business leaders) hide their money and exploit secretive offshore tax regimes. Dr Kimberly Kay Hoang is a Professor of Sociology at the University of Chicago, and after six years of research, hundreds of interviews and travelling 350,000 miles, she published Spiderweb Capitalism: How Global Elites Exploit Frontier Markets. She uncovered the mechanisms behind the movement of money into and out of Southeast Asia, and how that money travels all over the world.